display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
multiple myeloma - 2nd line (L2)
ovarian cancer (OC)
poly ADP-ribose polymerase (PARP) inhibitor
niraparib ENGOT-OV16/NOVA
olaparib PAOLA-1/ENGOT-ov25 SOLO 1 SOLO 3 SOLO2/ENGOT-Ov21 Ledermann
rucaparib ARIEL3 ARIEL4

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons